Active Pharmaceutical Ingredientia
| Progestogen et Estrogen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Progesterone | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pregnenolone | In domo |
Kosher | 145-13-1 |
| Medroxyprogesterone Acetate | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetate | CP/EP/USP | DMF in processususus | 595-33-5 |
| Mifepristone | CP/IP | DMF/GMP | 84371-65-3 |
| Cyproterone Acetate | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| Levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Norethisterone |
CP/EP/USP/JP |
DMF in processususus |
68-22-4 |
| Norethisterone Acetate |
EP/USP |
DMF in processususus |
51-98-9 |
| Norethisterone Enanthate |
In domo |
Sub R&D |
3836-23-5 |
| Drospirenone | EP/USP | DMF | 67392-87-4 |
| Gestodene | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | Sub R&D | 50-27- 1 |
| Ethinyl Estradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerate | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol Cypionatus |
USP | DMF in processususus |
313-06-4 |
| Promestriene |
In domo |
Sub R&D |
39219-28-8 |
| Tibolone | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | Sub R&D | 129453-61-8 |
| Exemestane | CP/EP/USP | Sub R&D | 107868-30-4 |
| Androgen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Finasteride | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasteride | EP/USP | CEP/FDA | 164656-23-9 |
| Abiraterone Acetate | CP/USP | DMF/GMP/WC | 154229-18-2 |
| Darolutamide |
In domo |
Sub R&D |
1297538-32-9 |
| Testosterone | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosterone Undecanoate | CP | DMF/WC | 5949-44-0 |
| Testosterone Cypionate | USP | DMF | 58-20-8 |
| Testosterone Enanthate |
USP/JP | Sub R&D |
315-37-7 |
| Testosterone Propionate |
CP/EP/USP/JP |
Sub R&D |
57-85-2 |
| DHEA | FP/In domo | DMF/WC/Kosher | 53-43-0 |
| Clascoterone | In domo | DMF in processususus | 19608-29-8 |
| Cortical Hormone | |||
| Product Name | Specification | Probatus | CAS Non. |
| Budesonide | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonide | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenone | EP | CEP in processuu | 107724-20-9 |
| Methylprednisolone | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Methylprednisolone Hemisuccinate | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Fluticasone Propionate | CP/EP/USP | DMF | 80474- 14-2 |
| Fluticasone Furoate | CP/EP | DMF in processususus | 397864-44-7 |
| Mometasone Furoate |
CP/EP/USP |
DMF in processususus |
Anhydrous (83919-23-7) Monohydratorum (141646-00-6) |
| Deflazacort |
In domo |
Sub R&D |
14484-47-0 |
| alii | |||
| Product Name | Specification | Probatus | CAS Non. |
| Oxcarbazepine | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslicarbazepine Acetate | CP/USP | DMF | 236395- 14-5 |
| Ganciclovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciclovir Hydrochloride | USP/EP | CEP in processu | 175865-59-5 |
| Oseltamivir Phosphate | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | In domo | Sub R&D | 1985606-14-1 |
| Revefenacin | In domo | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
In domo |
Sub R&D |
1190389-15-1 |
| Escitalopram Oxalate | CP/EP/USP | DMF in processusus | 219861-08-2 |
| Citalopram Hydrobromide |
CP/EP/USP |
DMF in processususus |
59729-32-7 |
| Cariprazine hydrochloride | In domo | DMF | 1083076-69-0 |
| Lasmiditan Succinate | In domo | DMF | 439239-92-6 |
| Iuliconazole | In domo | DMF | 187164-19-8 |
| Nintedanib Esylate |
In domo |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | In domo | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | Sub R&D | 171596-29-5 |
| Relugolix | In domo | DMF in processusus | 737789-87-6 |
| Ruxolitinib phosphate |
In domo |
DMF in processususus |
1092939-17-7 |
| Abemaciclib |
In domo |
Sub R&D |
1231929-97-7 |
| Phloroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-Trimethoxybenzene |
CP/In-domus |
GMP |
621-23-8 |
| Acidum Ursodeoxycholic | EP/USP/JP | Sub R&D | 128-13-2 |
| Tauroursodeoxycholic Acid |
In domo |
Sub R&D |
14605-22-2 |
| Cura |
CP/EP/USP/JP |
Sub R&D |
57-88-5 |
| Omega-3-Acid Ethyl Ethers 90 |
EP/USP |
DMF in processususus |
-- |
| Medium-Chain Triglycerides |
CP/USP/EP |
DMF |
-- |
| Benzalkonium Chloride |
USP/EP/JP |
CEP in processuu |
8001-54-5 |
| Oleum olivae (For Iniectio) |
CP/USP/EP/JP |
DMF in processususus |
8001-25-0 |
| Ovum phospholipids (nam Iniectio) |
CP/USP/EP |
DMF |
93685-90-6 |
| PORTIO |
In domo |
DMF in processususus |
203787-91-1 |
Acetate Abiraterone CP,USP specificationes habet. DMF, WC available.
Drospirenone EP,USP specificationes habet. DMF probatus.
Medroxyprogesterone Acetate USPãEPã IPãJP et KP habet. DMF, GMP praesto est.
Oxcarbazepinum habet CP, EP et USP specifications. CEP et DMF in promptu, GMP approbata.
Ganciclovir approbavit CP , EP, USP specificationem.DMF et GMP.
Nintedanib Esylate in-domus specification.DMF praesto est.